By Michael Franco April 03, 2025 Researcher Kanta Horie from Washington University analyzes a blood sample using a mass spectrometer that measures protein levels Matt Miller View 2 Images It wasn’t that long ago that the only way to test for Alzheimer’s disease was to perform an autopsy on someone who had been suffering from dementia...
Tag: <span>Alzheimer’s disease</span>
Post
Alzheimer’s early detection tests using video games may be as effective as blood tests
by Kathleen O’Brien, Rutgers University Credit: Rutgers University Alzheimer’s early detection tests using video games developed by Rutgers-Newark researchers may help spot the disease years before symptoms are noticeable and provide a noninvasive form of dementia screening. The innovative Rutgers dementia tests match the results of a new generation of blood tests that reveal biomarkers for...
Post
Key differences between visual and memory-led Alzheimer’s discovered
by University College London Credit: Unsplash/CC0 Public Domain Differences in the distribution of certain proteins and markers in the brain may explain why some people first experience vision changes instead of memory loss in Alzheimer’s disease, finds a new study by UCL researchers. Posterior cortical atrophy (PCA) is a rare form of Alzheimer’s disease that, rather...
Post
Senolytics target Alzheimer’s-linked brain enzymes without harming healthy ones
“This work provides new opportunities for the development of the next generation of ChE inhibitors that specifically target AChE and BChE associated with AD pathology.”Peer-Reviewed Publication Impact Journals LLC FacebookXLinkedInWeChatBlueskyMessageWhatsAppEmail image: Figure 10. Structural components and amino acid residues that are essential for the catalytic activity of acetylcholinesterase (AChE) and butyrylcholinesterse (BChE). (A) 2D depiction of...
Post
Novel Alzheimer’s drug candidate reduces inflammation and protects neurons
by University of Barcelona Credit: ACS Pharmacology & Translational Science (2025). DOI: 10.1021/acsptsci.4c00629 Alzheimer’s disease, the most common cause of dementia, is currently incurable. The current drugs available have very limited efficacy and only in mild stages of the disease. A team from the University of Barcelona has developed a promising therapeutic candidate to treat this disease, which...
Post
Highly accurate blood test diagnoses Alzheimer’s disease, measures extent of dementia
Could help determine which patients are likely to benefit from new Alzheimer’s drugsPeer-Reviewed Publication WashU Medicine FacebookXLinkedInWeChatBlueskyMessageWhatsAppEmail image: WashU Medicine researcher Kanta Horie, PhD, places a sample in a mass spectrometer that measures protein levels in blood plasma and other fluids. Horie co-led the development of a blood test for Alzheimer’s disease that diagnoses and...
Post
Lilly to connect patients to telehealth providers of Alzheimer’s care
Eli Lilly is expanding its direct-to-consumer telehealth platform, LillyDirect, to include care for Alzheimer’s disease. It’ll connect patients with Synapticure, another telehealth company, which will arrange for virtual diagnoses and care navigation — but not drug delivery, since treatments like Lilly’s new infusion drug Kisunla require in-person administration. Lilly is framing this as an effort to streamline...
Post
Study confirms accuracy of blood test for early Alzheimer’s detection in Asian populations
by National University of Singapore Credit: Karolina Grabowska from Pexels A study in Alzheimer’s & Dementia has demonstrated the high accuracy of plasma p-tau217 as a blood-based biomarker for detecting abnormal brain beta-amyloid (Aβ) pathology, a hallmark of Alzheimer’s disease (AD). More significantly, the study validates its effectiveness even in individuals with cerebrovascular disease (CeVD), which is highly...
Post
Anti-amyloid drug shows signs of preventing Alzheimer’s dementia
by Washington University in St. Louis Randall J. Bateman, MD, the Charles F. and Joanne Knight Distinguished Professor of Neurology at WashU Medicine, is the study director of an international clinical trial that finds an anti-amyloid drug can delay the onset of cognitive decline if given many years before symptoms of Alzheimer’s disease arise. The participants...
Post
Latest Alzheimer’s drug shown less effective in females than males
by McGill University Credit: Unsplash/CC0 Public Domain Since becoming only the second Alzheimer’s-modifying drug to gain American Federal Drug Administration approval in 2023, sales of lecanemab, known by its brand name Leqembi, have risen steadily, reaching $87 million USD in the last quarter of 2024. In its Phase 3 clinical trial, lecanemab slowed cognitive decline by 27% overall,...